The global stem cells market size was exhibited at USD 22.32 billion in 2022 and is projected to hit around USD 68.72 billion by 2032, growing at a CAGR of 11.9% during the forecast period 2023 to 2032.
Key Pointers:
Stem cells Market Report Scope
| Report Coverage | Details |
| Market Size in 2023 | USD 24.98 Billion |
| Market Size by 2032 | USD 68.72 Billion |
| Growth Rate from 2023 to 2032 | CAGR of 11.9% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | Product, application, technology, therapy, end-use, region |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America and Middle East & Africa |
Stem cells are cells that can differentiate into a variety of other cells, eventually forming organs or tissues. Many studies have been conducted over the years to assess the true potential of stem cells, leading to a variety of applications in the fields of genetic disease treatment, neurological disorders, oncology, and organ regeneration. The market is driven by the rising number of banks, growing focus on increasing therapeutic potential of these products, and extensive research for the development of regenerative medicines, among other factors.
The growing focus on regenerative therapies is fueling market expansion. iPSCs are becoming increasingly popular for the creation of customized cellular therapies, and opening up new possibilities in regenerative medicine. For instance, in September 2020, researchers from Duke-NUS and Monash University discovered the first stem cell that can aid in the treatment of placenta issues during pregnancy. The researchers devised a new method for producing induced trophoblast stem cells that can be used to generate placenta cells. The research will aid in the development of an in-vitro human placenta model and pave the way for future therapies.
Moreover, COVID-19 is acting as a catalyst for promoting the market growth. Several countries such as U.S., China, and Iran, have started conducting clinical trials using cellular therapies for treatment of COVID-19 infections. Furthermore, the use of cell therapy in the treatment of COVID-19 patients has yielded excellent results, which is fueling market expansion. In January 2020, a group of researchers in Beijing, China, tested stem cell treatment on patients to see if it was beneficial against COVID-19. The study found that administering intravenous clinical-grade MSCs to COVID-19 patients during first trial of treatment, improved their functional results and promoted enhanced recovery.
Increasing prevalence of cancer is one of the key factors contributing to the growth over the forecast period. Failure of combination therapy and chemotherapy for treatment of cancer has led to the shift in preference of physicians from such therapies to autologous and allogeneic stem cell therapy, thereby boosting the growth. Moreover, key market players and the government bodies are continuously investing in cancer research. For instance, in November 2021, California Institute for Regenerative Medicine invested USD 4 million in therapy targeting patients with acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL)
Introduction of novel technologies for the usage and adoption of cell based therapy is expected to boost the growth over the forecast period. Automation in adult stem cell & cord blood processing and storage are the key technologies expected to positively influence the market growth. For instance, various scientists are aiming for the approval of safe, and successful treatments using stem cells in a broad range of diseases. In 2021, companies such as Biotech Cellino invested USD 75 million in an effort to merge Artificial Intelligence technology for the development of automated stem cell manufacturing, that has the ability to regularizing access to cell treatments while aiming to be cost effective.
On the other hand, high cost of therapy is expected to hinder the market growth. For example, Bio informant, a stem cell research firm, reported that the cost of stem cell therapy ranges between USD 5,000 and USD 8,000 per patient, with some cases costing as much as USD 25,000 or more depending on the complexity of the procedure. Furthermore, restrictions on stem cell research activities have traditionally hampered embryonic stem cell growth, resulting in a meager share of the total market despite its advantages.
North America accounted for the largest revenue share of 44.8% in 2022. Presence of innovators and key market players has resulted into higher penetration of market products in the region. North America leads the market owing to strong biotechnology industry, presence of key players, extensive R&D and promotion of personalized medicines. The region accounts for the highest revenue share. Moreover, growth in this region can be further attributed to rising government initiative for promoting stem cell therapies. For instance, in March 2020, the government of Canada invested around USD 7 million in regenerative medicine and stem cell research. It will support 9 transnational projects and 4 clinical trials in the country for growing regenerative medicine sector
Some of the prominent players in the Stem cells Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global stem cells market.
By Product
By Application
By Technology
By Therapy
By End-user
By Region
Chapter 1. Introduction
1.1 Market Segmentation & Scope
1.1.1 Estimates And Forecast Timeline
1.2 Research Technologyology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 nova one advisor’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: Commodity flow approach
1.6.1.2 Approach 2: Country-wise market estimation using bottom-up approach
1.7 Global Market: CAGR Calculation
1.8 Research Assumptions
1.9 List of Secondary Sources
1.10 List of Primary Sources
1.11 Objectives
1.11.1 Objective 1:
1.11.2 Objective 2:
1.12 List Of Abbreviations
Chapter 2 Market Definitions
Chapter 3 Executive Summary
3.1 Market Summary
Chapter 4 Global Stem Cells Market Market Variables, Trends, & Scope
4.1 Stem Cells Market Lineage Outlook
4.1.1 Parent Market Outlook
4.2 Penetration and Growth Prospect Mapping
4.3 Regulatory Framework
4.4 Market Driver Analysis
4.4.1 Ongoing Developments In Regenerative Medicine
4.4.2 Rising Funds For Accelerating Stem Cell Research
4.4.3 Growing Demand For Stem Cell Banking
4.4.4 Increasing Prevalence Of Genetic Disorders
4.5 Market Restraint Analysis
4.5.1 Ethical Concern Related To Stem Cell Research
4.5.1 Lack Of A Well-Defined Regulatory Framework In Certain Applications Of Stem Cell
4.6 Key Opportunities
4.6.1 Demand For Cell & Gene Therapies
4.7 Key Challenge
4.7.1 Technical Limitations Associated With Manufacturing Processes
4.8 Stem Cells Market - Pestle Analysis
4.9 Industry Analysis - Porter’s
4.10 Major Deals And Strategic Alliances Analysis
4.10.1 Joint Ventures
4.10.2 Mergers And Acquisitions
4.10.3 Licensing And Partnership
4.10.4 Technology Collaborations
4.10.5 Strategic Divestments
4.11 COVID-19 Impact Analysis
Chapter 5 Stem Cells Market - Segment Analysis, by Product, 2018 - 2032
5.1 Global Stem Cells Market: Product Movement Analysis
5.2 Adult Stem Cells (ASCs)
5.2.1 Adult Stem Cells (Ascs) Market Estimates And Forecast, 2018 - 2032
5.2.2 Hematopoietic Stem Cells (Blood Stem Cells)
5.2.2.1 Hematopoietic stem cells (blood stem cells) market estimates and forecasts, 2018 - 2032
5.2.3 Mesenchymal Stem Cells
5.2.3.1 Mesenchymal stem cells market estimates and forecasts, 2018 - 2032
5.2.4 Neural Stem Cells
5.2.4.1 Neural stem cells market estimates and forecasts, 2018 - 2032
5.2.5 Epithelial/Skin Stem Cells
5.2.5.1 Epithelial/Skin stem cells market estimates and forecasts, 2018 - 2032
5.2.6 Other Adult Stem Cells
5.2.6.1 Other adult stem cells market estimates and forecasts, 2018 - 2032
5.3 Human Embryonic Stem Cells
5.3.1 Human Embryonic Stem Cells Market Estimates And Forecast, 2018 - 2032
5.4 Induced Pluripotent Stem Cells
5.4.1 Induced Pluripotent Stem Cells Market Estimates And Forecast, 2018 - 2032
5.5 Very Small Embryonic Like Stem Cells
5.5.1 Very Small Embryonic Like Stem Cells Market Estimates And Forecast, 2018 - 2032
Chapter 6 Stem Cells Market- Segment Analysis, by Application, 2018 - 2032
6.1 Stem Cells Market: Application Movement Analysis
6.2 Regenerative Medicine
6.2.1 Regenerative Medicine Market Estimates And Forecast, 2018 - 2032
6.2.2 Neurology
6.2.2.1 Neurology market estimates and forecasts, 2018 - 2032
6.2.3 Orthopedics
6.2.3.1 Orthopedics market estimates and forecasts, 2018 - 2032
6.2.4 Oncology
6.2.4.1 Oncology market estimates and forecasts, 2018 - 2032
6.2.5 Hematology
6.2.5.1 Hematology market estimates and forecasts, 2018 - 2032
6.2.6 Cardiovascular and Myocardial Infraction
6.2.6.1 Cardiovascular and myocardial infraction market estimates and forecasts, 2018 - 2032
6.2.7 Injuries
6.2.7.1 Injuries market estimates and forecasts, 2018 - 2032
6.2.8 Diabetes
6.2.8.1 Diabetes market estimates and forecasts, 2018 - 2032
6.2.9 Liver Disorder
6.2.9.1 Liver Disorder market estimates and forecasts, 2018 - 2032
6.2.10 Incontinence
6.2.10.1 Incontinence market estimates and forecasts, 2018 - 2032
6.2.11 Others
6.2.11.1 Others market estimates and forecasts, 2018 - 2032
6.3 Drug Discovery and Development
6.3.1 Drug Discovery And Development Market Estimates And Forecast, 2018 - 2032
Chapter 7 Stem Cells Market - Segment Analysis, by Technology, 2018 - 2032
7.1 Global Stem Cells Market: Technology Movement Analysis
7.2 Cell Acquisition
7.2.1 Cell Acquisition Market Estimates And Forecast, 2018 - 2032
7.2.2 Bone Marrow Harvest
7.2.2.1 Bone Marrow Harvest market estimates and forecasts, 2018 - 2032
7.2.3 Umbilical Blood Cord
7.2.3.1 Umbilical Blood Cord market estimates and forecasts, 2018 - 2032
7.2.4 Apheresis
7.2.4.1 Apheresis market estimates and forecasts, 2018 - 2032
7.3 Cell Production
7.3.1 Cell Production Market Estimates And Forecast, 2018 - 2032
7.3.2 Therapeutic Cloning
7.2.3.1 Therapeutic Cloning market estimates and forecasts, 2018 - 2032
7.3.3 In Vitro Fertilization
7.3.3.1 In Vitro Fertilization market estimates and forecasts, 2018 - 2032
7.3.4 Cell Culture
7.3.4.1 Cell Culture market estimates and forecasts, 2018 - 2032
7.3.5 Isolation
7.3.5.1 Isolation market estimates and forecasts, 2018 - 2032
7.4 Cryopreservation
7.4.1 Cryopreservation Market Estimates And Forecast, 2018 - 2032
7.5 Expansion And Sub-Culture
7.5.1 Expansion And Sub-Culture Market Estimates And Forecast, 2018 - 2032
Chapter 8 Stem Cells Market - Segment Analysis, By Therapy, 2018 - 2032
8.1 Global Stem Cells Market: Therapy Movement Analysis
8.2 Autologous
8.2.1 Autologous Market Estimates And Forecast, 2018 - 2032
8.3 Allogenic
8.3.1 Allogenic Market Estimates And Forecast, 2018 - 2032
Chapter 9 Stem Cells Market - Segment Analysis, By End-User, 2018 - 2032
9.1 Global Stem Cells Market: End-User Movement Analysis
9.2 Pharmaceutical And Biotechnology Companies
9.2.1 Pharmaceutical And Biotechnology Companies Market Estimates And Forecast, 2018 - 2032
9.3 Hospitals & Cell Banks
9.3.1 Hospitals & Cell Banks Market Estimates And Forecast, 2018 - 2032
9.4 Academic & Research Institutes
9.4.1 Academic & Research Institutes Market Estimates And Forecast, 2018 - 2032
Chapter 10 Stem Cells Market: - Segment Analysis, By Region, 2018 - 2032
10.1 Stem Cells Market: Regional Movement Analysis
10.2 North America
10.2.1 North America Market Estimates And Forecast, 2018 - 2032
10.2.2 U.S.
10.2.2.1 U.S. market estimates and forecast, 2018 - 2032
10.2.3 Canada
10.2.3.1 Canada market estimates and forecast, 2018 - 2032
10.3 Europe
10.3.1 Europe Market Estimates And Forecast, 2018 - 2032
10.3.2 U.K.
10.3.2.1 U.K. market estimates and forecast, 2018 - 2032
10.3.3. Germany
10.3.3.1 Germany market estimates and forecast, 2018 - 2032
10.3.4 France
10.3.4.1 France market estimates and forecast, 2018 - 2032
10.3.5. Italy
10.3.5.1 Italy market estimates and forecast, 2018 - 2032
10.3.5 Spain
10.3.5.1 Spain market estimates and forecast, 2018 - 2032
10.4 Asia Pacific
10.4.1 Asia Pacific Market Estimates And Forecast, 2018 - 2032
10.4.2 Japan
10.4.2.1 Japan market estimates and forecast, 2018 - 2032
10.4.3 China
10.4.3.1 China market estimates and forecast, 2018 - 2032
10.4.4 India
10.4.4.1 India Market Estimates And Forecast, 2018 - 2032
10.4.5 South Korea
10.4.5.1 South Korea Market Estimates And Forecast, 2018 - 2032
10.4.6 Australia
10.4.6.1 Australia Market Estimates And Forecast, 2018 - 2032
10.5 Latin America
10.5.1 Latin America Market Estimates And Forecast, 2018 - 2032
10.5.2 Brazil
10.5.2.1 Brazil Market Estimates And Forecast, 2018 - 2032
10.5.3 Mexico
10.5.3.1 Mexico Market Estimates And Forecast, 2018 - 2032
10.5.4 Argentina
10.5.4.1 Argentina market estimates and forecast, 2018 - 2032
10.6 Middle East & Africa (MEA)
10.6.1 Middle East & Africa Market Estimates And Forecast, 2018 - 2032
10.6.1 South Africa
10.6.1.1 South Africa Market Estimates And Forecast, 2018 - 2032
10.6.2 Saudi Arabia
10.6.2.1 Saudi Arabia market estimates and forecast, 2018 - 2032
10.6.3 UAE
10.6.3.1 UAE market estimates and forecast, 2018 - 2032
Chapter 11 Competitive Landscape
11.1 Public Companies
11.1.1 Company Market Position Analysis
11.1.2 Competitive Dashboard Analysis
11.1.3 Strategic Framework
11.2 Private Companies
11.2.1 List Of Key Emerging Companies/Technology Disruptors/Innovators
11.2.2 Regional Network Map
11.3 Company Profiles
11.3.1 ADVANCED CELL TECHNOLOGY, INC.
11.3.1.1 Company Overview
11.3.1.2 Financial Performance
11.3.1.3 Product Benchmarking
11.3.1.4 Strategic Initiatives
11.3.2 STEMCELL Technologies, Inc.
11.3.2.1 Company Overview
11.3.2.2 Financial Performance
11.3.2.3 Product Benchmarking
11.3.2.4 Strategic Initiatives
11.3.3 CELLULAR ENGINEERING TECHNOLOGIES INC.
11.3.3.1 Company Overview
11.3.3.2 Financial Performance
11.3.3.3 Product Benchmarking
11.3.3.4 Strategic Initiatives
11.3.4 CELLGENIX GmbH
11.3.4.1 Company Overview
11.3.4.2 Financial Performance
11.3.4.3 Product Benchmarking
11.3.4.4 Strategic Initiatives
11.3.5 PROMOCELL GMBH
11.3.5.1 Company Overview
11.3.5.2 Financial Performance
11.3.5.3 Product Benchmarking
11.3.5.4 Strategic Initiatives
11.3.6 LONZA
11.3.6.1 Company Overview
11.3.6.2 Financial Performance
11.3.6.3 Product Benchmarking
11.3.6.4 Strategic Initiatives
11.3.7 KITE PHARMA
11.3.7.1 Company Overview
11.3.7.2 Financial Performance
11.3.7.3 Product Benchmarking
11.3.7.4 Strategic Initiatives
11.3.8 CELLARTIS AB
11.3.8.1 Company Overview
11.3.8.2 Financial Performance
11.3.8.3 Product Benchmarking
11.3.8.4 Strategic Initiatives
11.3.9 ANGEL BIOTECHNOLOGY
11.3.9.1 Company Overview
11.3.9.2 Financial Performance
11.3.9.3 Product Benchmarking
11.3.9.4 Strategic Initiatives
11.3.10 BRAINSTORM CELL THERAPEUTICS
11.3.10.1 Company Overview
11.3.10.2 Financial Performance
11.3.10.3 Product Benchmarking
11.3.10.4 Strategic Initiatives
11.3.11 CELGENE CORPORATION
11.3.11.1 Company Overview
11.3.11.2 Financial Performance
11.3.11.3 Product Benchmarking
11.3.11.4 Strategic Initiatives
11.3.12 OSIRIS THERAPEUTICS, INC.
11.3.12.1 Company Overview
11.3.12.2 Financial Performance
11.3.12.3 Product Benchmarking
11.3.12.4 Strategic Initiatives
11.3.13 GENEA BIOCELLS
11.3.13.1 Company Overview
11.3.13.2 Financial Performance
11.3.13.3 Product Benchmarking
11.3.13.4 Strategic Initiatives
11.3.14 BIOHEART INC.
11.3.14.1 Company Overview
11.3.14.2 Financial Performance
11.3.14.3 Product Benchmarking
11.3.14.4 Strategic Initiatives
11.3.15 WAISMAN BIOMANUFACTURING
11.3.15.1 Company Overview
11.3.15.2 Financial Performance
11.3.15.3 Product Benchmarking
11.3.15.4 Strategic Initiatives
11.3.16 TIGENIX
11.3.16.1 Company Overview
11.3.16.2 Financial Performance
11.3.16.3 Product Benchmarking
11.3.16.4 Strategic Initiatives
11.3.17 CALADRIUS
11.3.17.1 Company Overview
11.3.17.2 Financial Performance
11.3.17.3 Product Benchmarking
11.3.17.4 Strategic Initiatives
11.3.18 GAMIDA CELL.
11.3.18.1 Company Overview
11.3.18.2 Financial Performance
11.3.18.3 Product Benchmarking
11.3.18.4 Strategic Initiatives
11.3.19 PLURISTEM THERAPEUTICS INC.
11.3.19.1 Company Overview
11.3.19.2 Financial Performance
11.3.19.3 Product Benchmarking
11.3.19.4 Strategic Initiatives
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers